Cargando…
Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia
BACKGROUND: Endocrinopathies and metabolic complications are common in beta thalassemia major patients receiving blood transfusions. Chelation therapy has a role in preventing or delaying such complications. However, patients may face difficulties adhering to chelation therapy for several reasons. A...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741829/ https://www.ncbi.nlm.nih.gov/pubmed/36514312 http://dx.doi.org/10.2147/JBM.S386594 |
_version_ | 1784848400036921344 |
---|---|
author | Habbash, Fatema Al-Bati, Wegdan Al-Hashim, Howra Aldossari, Maryam Alali, Ahmed Alalyani, Khalid Al-Ebrahim, Zainab Hamed, Nouf Eraqe, Samma Binayfan, Ziyad Al Marri, Azzam Aljaber, Thamer |
author_facet | Habbash, Fatema Al-Bati, Wegdan Al-Hashim, Howra Aldossari, Maryam Alali, Ahmed Alalyani, Khalid Al-Ebrahim, Zainab Hamed, Nouf Eraqe, Samma Binayfan, Ziyad Al Marri, Azzam Aljaber, Thamer |
author_sort | Habbash, Fatema |
collection | PubMed |
description | BACKGROUND: Endocrinopathies and metabolic complications are common in beta thalassemia major patients receiving blood transfusions. Chelation therapy has a role in preventing or delaying such complications. However, patients may face difficulties adhering to chelation therapy for several reasons. AIM: To evaluate endocrine complications in beta thalassemia major patients (2–30 years) in the Eastern Province of Saudi Arabia and compare the onset of endocrine complications among compliant and noncompliant patients. Moreover, we assessed the barriers that hinder compliance with chelating therapy. METHODS: A cross-sectional study was conducted on 89 patients (43 males and 46 females) aged 2 to 30 years attending different hospitals in the Eastern Province of Saudi Arabia. A semi-structured questionnaire was used to collect demographic data and medical histories. The questionnaires were completed by face-to-face interviews with the patients or their caregivers, and the required laboratory data were retrieved from the medical records of patients. RESULTS: The most prevalent abnormality was underweight detected in (40.9%) of patients, followed by subclinical hypothyroidism (37.7%), short stature (35.2%), hypothyroidism in (17.0%) and diabetes mellitus in (13.6%). A significant difference between those who were compliant with iron chelation therapy and those who were not in terms of the prevalence of short stature (P value=0.05) and hypothyroidism (P value=0.05). The percentage of patients who were not compliant with chelation therapy was 21.6% and 9.1% of patients were not taking them at all. CONCLUSION: Despite the role of chelation therapy in the management of iron overload, the risk of secondary endocrine and metabolic complications remained considerable. Subclinical hypothyroidism and short stature were the most frequent endocrine complications encountered in this study. |
format | Online Article Text |
id | pubmed-9741829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-97418292022-12-12 Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia Habbash, Fatema Al-Bati, Wegdan Al-Hashim, Howra Aldossari, Maryam Alali, Ahmed Alalyani, Khalid Al-Ebrahim, Zainab Hamed, Nouf Eraqe, Samma Binayfan, Ziyad Al Marri, Azzam Aljaber, Thamer J Blood Med Original Research BACKGROUND: Endocrinopathies and metabolic complications are common in beta thalassemia major patients receiving blood transfusions. Chelation therapy has a role in preventing or delaying such complications. However, patients may face difficulties adhering to chelation therapy for several reasons. AIM: To evaluate endocrine complications in beta thalassemia major patients (2–30 years) in the Eastern Province of Saudi Arabia and compare the onset of endocrine complications among compliant and noncompliant patients. Moreover, we assessed the barriers that hinder compliance with chelating therapy. METHODS: A cross-sectional study was conducted on 89 patients (43 males and 46 females) aged 2 to 30 years attending different hospitals in the Eastern Province of Saudi Arabia. A semi-structured questionnaire was used to collect demographic data and medical histories. The questionnaires were completed by face-to-face interviews with the patients or their caregivers, and the required laboratory data were retrieved from the medical records of patients. RESULTS: The most prevalent abnormality was underweight detected in (40.9%) of patients, followed by subclinical hypothyroidism (37.7%), short stature (35.2%), hypothyroidism in (17.0%) and diabetes mellitus in (13.6%). A significant difference between those who were compliant with iron chelation therapy and those who were not in terms of the prevalence of short stature (P value=0.05) and hypothyroidism (P value=0.05). The percentage of patients who were not compliant with chelation therapy was 21.6% and 9.1% of patients were not taking them at all. CONCLUSION: Despite the role of chelation therapy in the management of iron overload, the risk of secondary endocrine and metabolic complications remained considerable. Subclinical hypothyroidism and short stature were the most frequent endocrine complications encountered in this study. Dove 2022-12-07 /pmc/articles/PMC9741829/ /pubmed/36514312 http://dx.doi.org/10.2147/JBM.S386594 Text en © 2022 Habbash et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Habbash, Fatema Al-Bati, Wegdan Al-Hashim, Howra Aldossari, Maryam Alali, Ahmed Alalyani, Khalid Al-Ebrahim, Zainab Hamed, Nouf Eraqe, Samma Binayfan, Ziyad Al Marri, Azzam Aljaber, Thamer Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia |
title | Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia |
title_full | Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia |
title_fullStr | Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia |
title_full_unstemmed | Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia |
title_short | Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia |
title_sort | endocrine complications and the effect of compliance with chelation therapy in patients with beta thalassemia major in eastern province of saudi arabia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741829/ https://www.ncbi.nlm.nih.gov/pubmed/36514312 http://dx.doi.org/10.2147/JBM.S386594 |
work_keys_str_mv | AT habbashfatema endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia AT albatiwegdan endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia AT alhashimhowra endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia AT aldossarimaryam endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia AT alaliahmed endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia AT alalyanikhalid endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia AT alebrahimzainab endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia AT hamednouf endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia AT eraqesamma endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia AT binayfanziyad endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia AT almarriazzam endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia AT aljaberthamer endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia |